Aging Up-regulates ARA55 in Stromal Cells, Inducing Androgen-mediated Prostate Cancer Cell Proliferation and Migration

Overview

Journal J Mol Histol

Specialty Biochemistry

Date 2016 May 15

PMID 27178620

Citations 3

Authors

Qingsong Zou

Di Cui

Shengjie Liang

Shujie Xia

Yifeng Jing

Bangmin Han

Affiliations

Soon will be listed here.

Abstract

Stromal cells in the peripheral zone (PZ) of the prostate from older males (PZ-old) could significantly promote Prostate cancer (PCa) growth compared with stromal cells from young males (PZ-young). But the mechanism is still unknown. In the co-culture system with PZ-old cells, Pc3/Du145 cells showed advanced proliferation and migration after Dihydrotestosterone (DHT) incubation, but DHT didn't show the similar effect in PZ-young co-culture system. Also, higher androgen/AR signal pathway activity and AR-related cytokines secretion (FGF-2, KGF, IGF-1) were found in PZ-old cells. As AR exprssison was equivalent in PZ-old and PZ-young cells, we focused on Androgen receptor associated protein-55(ARA55), a stromal-specific androgen receptor (AR) coactivator. ARA55 expression was higher in PZ-old cells compared with PZ-young cells in vitro. After knocking down ARA55 expression in PZ-old cells, the PCa growth- promoting effect from the PZ-old cells was diminished, which may be explained by the decreased the progressive cytokines secretion (FGF-2, KGF, IGF-1) from PZ-old stromal cells. In vivo, the consistent results were also found: PZ-old cells promoted prostate cancer cells growth, but this effect receded when knocking down ARA55 expression in PZ-old cells. From our study, we found PZ stromal cells presented age-related effects in proliferation and migration of prostate cancer cells in the androgen/AR dependent manner. As aging increased, more ARA55 were expressed in PZ stromal cells, leading to more sensitive androgen/androgen receptor (AR) signal pathway, then constituting a more feasible environment to cancer cells.

Citing Articles

Reduced Proline-Rich Tyrosine Kinase 2 Promotes Tumor Metastasis by Activating Epithelial-Mesenchymal Transition in Colorectal Cancer.

Wu F, Zhang K, Song Z, Zhou Q, Sun H, Tan Z Dig Dis Sci. 2024; 69(11):4098-4107.

PMID: 39414740 DOI: 10.1007/s10620-024-08643-y.

Common variation at 16p11.2 is associated with glycosuria in pregnancy: findings from a genome-wide association study in European women.

Lee M, McMahon G, Karhunen V, Wade K, Corbin L, Hughes D Hum Mol Genet. 2020; 29(12):2098-2106.

PMID: 32227112 PMC: 7390941. DOI: 10.1093/hmg/ddaa054.

HIC-5 in cancer-associated fibroblasts contributes to esophageal squamous cell carcinoma progression.

Du X, Xu Q, Pan D, Xu D, Niu B, Hong W Cell Death Dis. 2019; 10(12):873.

PMID: 31740661 PMC: 6861248. DOI: 10.1038/s41419-019-2114-z.

References

Poukka H, Karvonen U, Yoshikawa N, Tanaka H, Palvimo J, Janne O . The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci. 2000; 113 ( Pt 17):2991-3001. DOI: 10.1242/jcs.113.17.2991. View

Lu Y, Jiang B, Zhao F, Cui D, Jiang Q, Yu J . Androgen receptors expressed by prostatic stromal cells obtained from younger versus older males exhibit opposite roles in prostate cancer progression. Asian J Androl. 2013; 15(5):672-8. PMC: 3881637. DOI: 10.1038/aja.2013.45. View

Acevedo V, Gangula R, Freeman K, Li R, Zhang Y, Wang F . Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007; 12(6):559-71. DOI: 10.1016/j.ccr.2007.11.004. View

Wang Y, Yu S, Wang X, Han B, Zhao F, Zhu G . Differences in phenotype and gene expression of prostate stromal cells from patients of varying ages and their influence on tumour formation by prostate epithelial cells. Asian J Androl. 2011; 13(5):732-41. PMC: 3739587. DOI: 10.1038/aja.2011.11. View

Niu Y, Altuwaijri S, Yeh S, Lai K, Yu S, Chuang K . Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A. 2008; 105(34):12188-93. PMC: 2527887. DOI: 10.1073/pnas.0804701105. View

Barclay W, Woodruff R, Craig Hall M, Cramer S . A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology. 2004; 146(1):13-8. PMC: 3033046. DOI: 10.1210/en.2004-1123. View

Zhao F, Han B, Yu S, Xia S . Tumor formation of prostate cancer cells influenced by stromal cells from the transitional or peripheral zones of the normal prostate. Asian J Androl. 2009; 11(2):176-82. PMC: 3735029. DOI: 10.1038/aja.2008.33. View

Mantzoros C, Tzonou A, Signorello L, Stampfer M, Trichopoulos D, Adami H . Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997; 76(9):1115-8. PMC: 2228109. DOI: 10.1038/bjc.1997.520. View

Xia S, Xu X, Xu C, Tang X . Characteristic pattern of human prostatic growth with age. Asian J Androl. 2003; 4(4):269-71. View

10.

Thomson A, Timms B, Barton L, Cunha G, Grace O . The role of smooth muscle in regulating prostatic induction. Development. 2002; 129(8):1905-12. DOI: 10.1242/dev.129.8.1905. View

11.

Copperman A, DeCherney A . Turn, turn, turn. Fertil Steril. 2006; 85(1):12-3. DOI: 10.1016/j.fertnstert.2005.07.1297. View

12.

Shang Y, Myers M, Brown M . Formation of the androgen receptor transcription complex. Mol Cell. 2002; 9(3):601-10. DOI: 10.1016/s1097-2765(02)00471-9. View

13.

Krtolica A, Parrinello S, Lockett S, Desprez P, Campisi J . Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001; 98(21):12072-7. PMC: 59769. DOI: 10.1073/pnas.211053698. View

14.

Park C, Bissell M, Barcellos-Hoff M . The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000; 6(8):324-9. DOI: 10.1016/s1357-4310(00)01756-1. View

15.

Cunha G, Hayward S, Wang Y, Ricke W . Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003; 107(1):1-10. DOI: 10.1002/ijc.11335. View

16.

Miyamoto H, Messing E, Chang C . Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004; 61(4):332-53. DOI: 10.1002/pros.20115. View

17.

Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View

18.

Oliver V, Poulios K, VENTURA S, Haynes J . A novel androgen signalling pathway uses dihydrotestosterone, but not testosterone, to activate the EGF receptor signalling cascade in prostate stromal cells. Br J Pharmacol. 2013; 170(3):592-601. PMC: 3791997. DOI: 10.1111/bph.12307. View

19.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

20.

Marker P, Donjacour A, Dahiya R, Cunha G . Hormonal, cellular, and molecular control of prostatic development. Dev Biol. 2003; 253(2):165-74. DOI: 10.1016/s0012-1606(02)00031-3. View